US Patent Issued to Regeneron Pharmaceuticals on April 14 for "Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof" (New York Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,780, issued on April 14, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof" was invented by Eric Smith (New York) and Nicholas J. Papadopoulos (LaGrangeville, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. A...